Home / Business and Economy / Boston Scientific Shares Plunge: Analysts Remain Bullish
Boston Scientific Shares Plunge: Analysts Remain Bullish
7 Feb
Summary
- Boston Scientific shares dropped nearly 20% this week.
- Analysts maintain bullish outlook despite stock's sharp decline.
- Watchman implant clinical study data may serve as a catalyst.
Boston Scientific Corp. experienced a significant stock selloff this week, with shares dropping nearly 20% following a disappointing profit forecast for 2026 and weaker-than-expected fourth-quarter growth in its Electrophysiology segment. This marks the stock's worst weekly decline since 2008, with Wednesday's 18% drop being its largest single-day loss in over 25 years.
Despite the sharp downturn, many analysts on Wall Street are maintaining their bullish stance. Prior to the earnings report, 35 out of 37 analysts tracked by Bloomberg had rated the stock as a 'buy.' Even after the results, the number of 'buy' ratings has increased, and the average price target remains substantially higher than the current trading price.
Analysts point to the company's continued revenue growth potential and attractive valuation following the selloff. A key potential catalyst highlighted is the upcoming clinical study data for the Watchman implant, expected in late March. However, some analysts note that uncertainty in the Electrophysiology segment may lead investors to await more visible signs of stability before re-engaging with the stock.
